Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 5/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816469 | 0.83 | ADRA1D (0.51) | MAPK10ALDH1A1BRD4USP2KDM4E | |
| SCHEMBL6235800 | 0.82 | ADRA1D (0.48) | MAPK10ALDH1A1BRD4USP2KDM4E | |
| SCHEMBL29001267 | 0.81 | MAPK10 (0.51) | MAPK10ALDH1A1BRD4USP2KDM4E | |
| SCHEMBL12876607 | 0.77 | BRD4 (0.58) | ALDH1A1BRD4SMN1; SMN2LMNA | |
| SCHEMBL15815917 | 0.77 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPK14MEN1KMT2A | |
| SCHEMBL14309643 | 0.75 | ALDH1A1 (0.37) | MAPK10ALDH1A1BRD4USP2KDM4E | |
| Ethane SCHEMBL13370815 | 0.74 | ALDH1A1 (0.51) | MAPK10ALDH1A1BRD4KDM4EMEN1 | |
| SCHEMBL16899407 | 0.73 | MAPK14 (0.53) | ALDH1A1BRD4KDM4EMAPK14SMN1; SMN2 | |
| SCHEMBL5812520 | 0.72 | L3MBTL1 (0.52) | MAPK14MEN1KMT2A | |
| SCHEMBL15836993 | 0.72 | ALDH1A1 (0.50) | MAPK10ALDH1A1BRD4KDM4EMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888375-B2 | Pyridinone diketo acids: inhibitors of HIV replication | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888375-B2 | Pyridinone diketo acids: inhibitors of HIV replication | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888375-B2 | Pyridinone diketo acids: inhibitors of HIV replication | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080020010-A1 | Pyridinone diketo acids: inhibitors of HIV replication | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020010-A1 | Pyridinone diketo acids: inhibitors of HIV replication | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020010-A1 | Pyridinone diketo acids: inhibitors of HIV replication | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092427-A1 | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy | TKT, DHFR, DTYMK | MAPK10 1865/4885ALDH1A1 1645/4885BRD4 2605/4885 |
| US-20080020010-A1 | Pyridinone diketo acids: inhibitors of HIV replication | DCK, PDXK, DTYMK | MAPK10 1131/4885ALDH1A1 2008/4885BRD4 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.